Afatinib (BIBW 2992)
|
|
|
- CAS-Nr.
- 439081-18-2
- Englisch Name:
- Afatinib (BIBW 2992)
- Synonyma:
- Afatinib Base;BIBW 2992;(E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide;N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide;2992;Tovok;CS-95;Afatinb;ToMtovok;BIBW-2292
- CBNumber:
- CB12470923
- Summenformel:
- C24H25ClFN5O3
- Molgewicht:
- 485.94
- MOL-Datei:
- 439081-18-2.mol
|
Afatinib (BIBW 2992) Eigenschaften
- Siedepunkt:
- 676.9±55.0 °C(Predicted)
- Dichte
- 1.380
- storage temp.
- Store at -20°C
- Löslichkeit
- ≥24.3 mg/mL in DMSO; insoluble in H2O; ≥42.1 mg/mL in EtOH with ultrasonic
- Aggregatzustand
- solid
- pka
- 12.06±0.43(Predicted)
- CAS Datenbank
- 439081-18-2
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizität (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
Afatinib (BIBW 2992) Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
In July 2013, the US FDA approved afatinib (also referred to as BIBW- 2992), for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) and with tumors that have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution. Afatinib functions as an irreversible inhibitor by covalently binding directly to the ATP-binding site in the kinase domains of both EGFR(Cys 773) andHER2 (Cys 805;HER-2 is the preferred dimerization partner of EGFR) resulting in downregulation of EGFR signaling. Afatinib is a potent inhibitor of wild-type and mutant forms (L858R) of EGFR (IC
50s of 0.5 and 0.4 nM, respectively), and HER2 (IC
50=14 nM), but about 100-fold more active against the gefitinib resistant L858R– T790M EGFR double mutant, with an IC
50 of 10 nM. Consistent with its in vitro activity, afatinib induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib. A synthetic route to afatinib that employs the displacement of a phenylsulfonyl group to install the (S)-3-hydoxytetrahydrofuran ring and a modified Horner–Wadsworth–Emmons reaction with {[4-(3-chloro-4- phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6-ylcarbamoyl]- methyl}-phosphonate and dimethylaminoacetaldehyde-hydrogen sulfite adduct to install the eneamide moiety, has been reported.
Verwenden
BIBW2992 (Afatinib, Tomtovok, Tovok) irreversibly inhibits EGFR/HER2 including EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively.
Afatinib (BIBW 2992) Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Afatinib (BIBW 2992) Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 387)Lieferanten
- Tovok
- Afatinb
- (S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dim
- Tovok, BIBW 2992
- BIBW 2992;TOVOK
- BIBW2992 Afatinib
- Afatinib (BIBW 2992)
- ToMtovok
- (S,E)-N-(4-(3-chloro-4-fluorophenylaMino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(diMethylaMino)but-2-enaMide
- (E)-N-(7-((S)-tetrahydrofuran-3-yloxy)-4-(3-chloro-4-fluorophenylaMino)quinazolin-6-yl)-4-(diMethylaMino)but-2-enaMide
- (S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimeth
- (S,E)-N-(4-(3-chloro-4-fluorophenylaMino)-7-(tetrahydrofuran-2-yloxy)quinazolin-6-yl)-4-(diMethylaMino)but-2-enaMide
- (S)-N-(4-((3-Chloro-4-fluorophenyl)aMino)-7-((tetrahydrofuran- 3-yl)oxy)quinazolin-6-yl)-4-(diMethylaMino)but-2-enaMide
- BIBW 2992 N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide
- Afatinib, Free Base
- Tofacitinib and its interMediate
- Afatinib, >=99%
- Afatinib (BIBW 2992)r
- Afatinib (BIBW 2992) powder
- (E/Z)-Afatinib
- Afatinib(cis-trans isomerismtautomers)
- Afatinib(W.S)
- AFATINIB; BIBW2992;BIBW-2292
- BIBW-2292
- CS-95
- TOVOK (BIBW-2992, Afatinib)
- 2992
- (S)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[(3-tetrahydrofuranyl)oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide
- [14C]Afatinib
- [14C] (S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dim
- 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-
- Cancer Treatment Afatinib CAS
- Medicine Grade Afatinib
- Afatinib (BIBW 2992) USP/EP/BP
- BIBW 2992
- N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide
- (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide
- Alfatinib
- The method for
- Afatinib Base
- Offer 439081-18-2 Afatinib (BIBW 2992)
- Afatinib 99%
- N-4-(3-Chloro-4-fluorophenyl)amino-7-(3S)-tetrahydro-furan-3-yloxy-6-quinazolinyl-4-(dimethylamino)but-2-enamide
- 439081-18-2
- 439081-18-0
- API
- Inhibitors
